[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Global Emergency Contraceptives Market, 2012-2023

January 2018 | 185 pages | ID: G7279B5F6DEEN
Precision Business Insights (PBI)

US$ 4,400.00

E-mail Delivery (PDF)

Download PDF Leaflet

Wire Transfer
Checkout Later
Need Help? Ask a Question
Global Emergency Contraceptives Market, provides emergency contraception methods are intended to prevent unwanted pregnancies after sexual intercourse. The commonly used emergency contraceptives are pills and copper-bearing intrauterine devices. Within emergency contraceptive pills are available in 3 compositions namely, combined estrogen and progestin pills, progestin-only (as Levonorgestrel) pills, and antiprogestin (as mifepristone) pills. Emergency contraceptives are different from normal contraceptives. The mechanism of action of the emergency contraceptive methods is delaying or preventing ovulation or fertilization, which is necessary during pregnancy. Both the methods are effective only before the pregnancy implanted. These procedures are ineffective after the implantation occurred.

The global emergency contraceptives market is expected to grow at an unprecedented CAGR due to increase in the global female population. Increase in the public awareness in making right decisions about their sexual and reproductive health, technological advancements and an increase in the development of effective female contraceptive drugs and devices, and availability of products in the market might fuel the emergency contraceptives market. Furthermore, low cost of the products, rise in the adoption of modern emergency contraceptives in developing countries, ease of administration of emergency contraceptive pills, and high effectiveness and convenience in emergency contraceptive devices might boost the global emergency contraceptives market. However, adverse effects like nausea, headache associated with the emergency contraceptive pills, lack of skilled professionals for the insertion of intrauterine devices, and product failures in some cases might hamper the emergency contraceptives market.

Emergency contraceptives market segmented on the basis of drug class, and distribution channel

Based on drug class, emergency contraceptives market has been segmented into the following:
  • Combined estrogen and progestin pills
  • Progestin-only (as Levonorgestrel) pills
  • Antiprogestin (as mifepristone) pills
  • Ulipristal acetate pills
Based on the distribution channel, emergency contraceptives market has been segmented into the following:
  • Hospital pharmacies
  • Retail pharmacies
  • Online pharmacies
  • Others
Market players investing heavily to manufacture emergency contraceptives to increase their share in the emergency contraceptives market. Launching of new products, collaborations, acquisitions and mergers, approvals as over the counter (OTC) product from various drug regulators such as U.S. Food and Drug Administration, and research and developments are some key strategies followed by various pharmaceutical companies to increase the share in the global emergency contraceptives market. For instance, in August 2010, U.S. Food and Drug Administration approved the Ella (Ulipristal acetate pills) as emergency contraceptive pills which are developed by HRA pharmaceuticals. Similarly, In February 2011, Teva Pharmaceuticals received an approval from the FDA for requesting non-prescription status for Plan B One-Step for women under the age of 17.

Geographically, the emergency contraceptives market has been segmented into following regions Viz. North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. North America expected to account for the major market share in the Emergency Contraceptives market followed by Europe and Asia-Pacific. This dominance in the North America region is owing to increase the emergency contraception (EC) market in U.S. driven by rising demand and less stringent market regulations. According to the Centres for Disease Control and Prevention (CDC), about 4% of women aged 15-44 have used emergency contraceptives in 2002, and it has increased to 11% from 2006-2010. Europe holds a key share in global emergency contraceptives market attributed to increasing the awareness about the use of pills, and ease of administration of the devices. A rise in the adoption of advanced contraceptives in emerging economies is the prime driving factor of the market. Asia-Pacific is an emerging region for emergency contraceptives market owing to increase in female population majorly in India and China. Low cost of the products and availability of drugs over the counter also fuel the emergency contraceptives market in Asia-Pacific region.

Some of the players in the emergency contraceptives market are Genetics NV (Belgium), Teva Pharmaceutical Industries Ltd. (Israel), Uniprix group (Canada), Gavis Pharmaceuticals LLC, (A Lupin Group Company) (U.S.), HRA Pharma (Paris), and Mankind Pharma (India) to name a few.
1. EXECUTIVE SUMMARY

2. GLOBAL EMERGENCY CONTRACEPTIVES MARKET INTRODUCTION

2.1. Global Emergency Contraceptives Market – Taxonomy
2.2. Global Emergency Contraceptives Market –Definitions
  2.2.1. Drugs
  2.2.2. Distribution Channel

3. GLOBAL EMERGENCY CONTRACEPTIVES MARKET DYNAMICS

3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Global Emergency Contraceptives Market Dynamics – Factors Impact Analysis
3.6. Global Emergency Contraceptives Market – Regulations
  3.6.1. U.S.
  3.6.2. Europe
  3.6.3. Japan
3.7. Global Emergency Contraceptives Market – Product Pipeline Analysis

4. GLOBAL EMERGENCY CONTRACEPTIVES MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 – 2023

4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
4.3. Market Oppurtunity Analysis

5. GLOBAL EMERGENCY CONTRACEPTIVES MARKET, BY DRUGS, 2012 - 2016 AND FORECAST, 2017 - 2023

5.1. Combined estrogen and progestin pills
  5.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  5.1.3. Market Opportunity Analysis
5.2. Progestin-only (as Levonorgestrel) pills
  5.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  5.2.3. Market Opportunity Analysis
5.3. Antiprogestin (as mifepristone) pills
  5.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  5.3.3. Market Opportunity Analysis
5.4. Ulipristal acetate pills
  5.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  5.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  5.4.3. Market Opportunity Analysis

6. GLOBAL EMERGENCY CONTRACEPTIVES MARKET FORECAST, BY DISTRIBUTION CHANNEL, 2012 - 2016 AND FORECAST, 2017 - 2023

6.1. Hospital Pharmacies
  6.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  6.1.3. Market Opportunity Analysis
6.2. Retail Pharmacies
  6.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  6.2.3. Market Opportunity Analysis
6.3. On-line Pharmacies
  6.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  6.3.3. Market Opportunity Analysis

7. GLOBAL EMERGENCY CONTRACEPTIVES MARKET FORECAST, BY REGION, 2012 - 2016 AND FORECAST, 2017 - 2023

7.1. North America
  7.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  7.1.3. Market Opportunity Analysis
7.2. Europe
  7.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  7.2.3. Market Opportunity Analysis
7.3. Asia-Pacific
  7.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  7.3.3. Market Opportunity Analysis
7.4. Latin America
  7.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  7.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  7.4.3. Market Opportunity Analysis
7.5. Middle East and Africa
  7.5.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  7.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  7.5.3. Market Opportunity Analysis
7.6. Global Emergency Contraceptives Market - Opportunity Analysis Index, By Drugs, By Distribution Channel, and Region, 2017 – 2023

8. NORTH AMERICA EMERGENCY CONTRACEPTIVES MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

8.1. Drugs Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
  8.1.1. Combined Estrogen and Progestin Pills
  8.1.2. Progestin-only (as Levonorgestrel) Pills
  8.1.3. Antiprogestin (as mifepristone) Pills
  8.1.4. Ulipristal Acetate Pills
  8.1.5. Others
8.2. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
  8.2.1. Hospital Pharmacies
  8.2.2. Retail Pharmacies
  8.2.3. On-line Pharmacies
8.3. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
  8.3.1. U.S.
  8.3.2. Canada
8.4. North America Emergency Contraceptives Market - Opportunity Analysis Index, By Drugs, By Distribution Channel and Country, 2017 – 2023
8.5. North America Emergency Contraceptives Market Dynamics – Trends

9. EUROPE EMERGENCY CONTRACEPTIVES MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

9.1. Drugs Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
  9.1.1. Combined Estrogen and Progestin Pills
  9.1.2. Progestin-only (as Levonorgestrel) Pills
  9.1.3. Antiprogestin (as mifepristone) Pills
  9.1.4. Ulipristal Acetate Pills
  9.1.5. Others
9.2. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
  9.2.1. Hospital Pharmacies
  9.2.2. Retail Pharmacies
  9.2.3. On-line Pharmacies
9.3. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
  9.3.1. Germany
  9.3.2. UK
  9.3.3. France
  9.3.4. Spain
  9.3.5. Italy
  9.3.6. Russia
  9.3.7. Poland
  9.3.8. Rest of Europe
9.4. Europe Emergency Contraceptives Market - Opportunity Analysis Index, Opportunity Analysis Index, By Drugs, By Distribution Channel and Country, 2017 – 2023
9.5. Europe Emergency Contraceptives Market Dynamics – Trends

10. ASIA-PACIFIC EMERGENCY CONTRACEPTIVES MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

10.1. Drugs Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
  10.1.1. Combined Estrogen and Progestin Pills
  10.1.2. Progestin-only (as Levonorgestrel) Pills
  10.1.3. Antiprogestin (as mifepristone) Pills
  10.1.4. Ulipristal Acetate Pills
  10.1.5. Others
10.2. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
  10.2.1. Hospital Pharmacies
  10.2.2. Retail Pharmacies
  10.2.3. On-line Pharmacies
10.3. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn),
Y-o-Y Growth (%), and Market Share (%)
  10.3.1. Japan
  10.3.2. China
  10.3.3. India
  10.3.4. ASEAN
  10.3.5. Australia & New Zealand
  10.3.6. Rest of Asia-Pacific
10.4. Asia-Pacific Emergency Contraceptives Market - Opportunity Analysis Index, By Drugs, By Distribution Channel and Country, 2017 – 2023
10.5. Asia-Pacific Emergency Contraceptives Market Dynamics – Trends

11. LATIN AMERICA EMERGENCY CONTRACEPTIVES MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

11.1. Drugs Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
  11.1.1. Combined Estrogen and Progestin Pills
  11.1.2. Progestin-only (as Levonorgestrel) Pills
  11.1.3. Antiprogestin (as mifepristone) Pills
  11.1.4. Ulipristal Acetate Pills
  11.1.5. Others
11.2. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
  11.2.1. Hospital Pharmacies
  11.2.2. Retail Pharmacies
  11.2.3. On-line Pharmacies
11.3. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
  11.3.1. Brazil
  11.3.2. Mexico
  11.3.3. Argentina
  11.3.4. Venezuela
  11.3.5. Rest of Latin America
11.4. Latin America Emergency Contraceptives Market - Opportunity Analysis Index, By Drugs, By Distribution Channel and Country, 2017 – 2023
11.5. Latin America Emergency Contraceptives Market Dynamics – Trends

12. MIDDLE EAST AND AFRICA EMERGENCY CONTRACEPTIVES MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

12.1. Drugs Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
  12.1.1. Combined Estrogen and Progestin Pills
  12.1.2. Progestin-only (as Levonorgestrel) Pills
  12.1.3. Antiprogestin (as mifepristone) Pills
  12.1.4. Ulipristal Acetate Pills
  12.1.5. Others
12.2. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
  12.2.1. Hospital Pharmacies
  12.2.2. Retail Pharmacies
  12.2.3. On-line Pharmacies
12.3. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
  12.3.1. Gulf Cooperation Council (GCC) Countries
  12.3.2. Israel
  12.3.3. South Africa
  12.3.4. Rest of MEA
12.4. MEA Emergency Contraceptives Market - Opportunity Analysis Index, By Drugs, By Distribution Channel and Country, 2017 – 2023
12.5. MEA Emergency Contraceptives Market Dynamics – Trends

13. COMPETITION LANDSCAPE

13.1. Strategic Dashboard of Top Market Players
13.2. Company Profiles (Introduction, Financial Analysis, Product & Service Offerings, Key Developments, Strategies, and SWOT Analysis)
  13.2.1. Gynetics NV (Belgium)
  13.2.2. Teva Pharmaceutical Industries Ltd. (Israel)
  13.2.3. Uniprix group (Canada)
  13.2.4. Gavis Pharmaceuticals LLC, (A Lupin Group Company) (U.S.)
  13.2.5. HRA Pharma (Paris)
  13.2.6. Mankind Pharma (India)

14. RESEARCH METHODOLOGY

15. KEY ASSUMPTIONS AND ACRONYMS


More Publications